Global Peptide Antibiotics Market - Industry Trends and Forecast to 2029

Market Analysis and Insights

Anti-infective and antitumor antibiotics with polypeptide chains are referred to as the peptide antibiotics. Ribosomal manufactured peptide antibiotics and non-ribosomal synthesised peptide antibiotics are the two types of peptide antibiotics. Peptide antibiotics have a number of advantages, including high effectiveness, specificity, and minimal toxicity.

• The peptide antibiotics is supportive and aims to reduce the severity of the symptoms of tumour. Data Bridge Market Research analyses that the peptide antibiotics market will grow at a CAGR of 5.50% during the forecast period of 2022 to 2029.

Peptide Antibiotics Market Dynamics

Major factors that are expected to boost the growth of the peptide antibiotics market in the forecast period are as follows:

• The rise in the cases of antibiotic resistance

The growing incidence of the infectious diseases around is one of major contributors of the peptide antibiotics market growth.

• The growing need for peptide antibiotics in hospitals and clinics

Growing prevalence of different types of cancer and increase in the incidence of chronic pain is further estimated to drive the peptide antibiotics market growth rate.

The increasing research and development activities in the field of peptide antibiotics due to the incidence and prevalence of cancer, rise in the geriatric population, and increased diagnosis rate of cancer.

Opportunities

In addition, the rise in the competition among the market players and rapid increase in the number of manufacturers will further provide potential opportunities for the growth of the peptide antibiotics market in the coming years.

Restraints/Challenges

On the other hand, the several side effects regarding the long term use of the peptide antibiotics is further projected to impede the growth of the peptide antibiotics market in the timeline period. However, the complicated manufacturing procedure of peptide antibiotic sterile injectable drugs might further challenge the growth of the peptide antibiotics market in the near future.

This peptide antibiotics market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on peptide antibiotics market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.

Patient Epidemiology Analysis

The peptide antibiotics market also provides you with detailed market analysis for patient analysis, prognosis and cures. Prevalence, incidence, mortality, adherence rates are some of the data variables that are available in the report. Direct or indirect impact analyses of epidemiology to market growth are analysed to create a more robust and cohort multivariate statistical model for forecasting the market in the growth period.

COVID-19 Impact on Peptide Antibiotics Market

The COVID-19 has negatively affected the market. The COVID-19 pandemic could have an impact on healthcare systems, procedures, and prescriptions. Antibiotic prescribing errors may have a role in the establishment and spread of antibiotic resistance. The current pandemic is related with an early decrease in overall antibiotic prescribing following COVID-19 emergence, but no statistically meaningful reduction in the long term, according to this quasi-experimental nationwide method carried out in the context of outpatient treatment in Portugal.

Global Peptide Antibiotics Market Scope

The peptide antibiotics market is segmented on the basis of product type, drugs, route of administration, indications and distribution channel. The growth amongst these segments will help you analyze meager growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.

Product Type

• Ribosomal Synthesized Peptide Antibiotics

• Non-ribosomal Synthesized Peptide Antibiotics

On the basis of product type, the peptide antibiotics market is segmented into ribosomal synthesized peptide antibiotics and non-ribosomal synthesized peptide antibiotics.

Drugs

• Daptomycin

• Dalbavancin

• Telavancin

• Others

On the basis of drugs, the peptide antibiotics market is segmented into daptomycin, dalbavancin, telavancin and others.

Route of Administration

• Oral

• Parenteral

• Topical

• Others

On the basis of route of administration, the peptide antibiotics market is segmented into oral, parenteral, topical and others.

Distribution Channel

• Hospitals
• Homecare
• Specialty Clinics
• Others

On the basis of distribution channel, the lissencephaly treatment market is also segmented into hospitals, homecare, specialty clinics and others.

Peptide Antibiotics Market Regional Analysis/Insights

The peptide antibiotics market is analysed and market size insights and trends are provided by country, product type, drugs, route of administration, indications and distribution channel as referenced above.

The countries covered in the peptide antibiotics market report are U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.

North America dominates the peptide antibiotics market due to the occurrence of major key players. Furthermore, the rise in the demand for antibiotics will further boost the growth of the peptide antibiotics market in the region during the forecast period.

Asia-Pacific is projected to observe significant amount of growth in the peptide antibiotics market due to the rise in the awareness of people towards their health. Moreover, the increase in the disposable income in the advancing countries is further anticipated to propel the growth of the peptide antibiotics market in the region in the coming years.

The country section of the report also provides individual market impacting factors and changes in regulations in the market domestically that impacts the current and future trends of the market. Data points such as new sales, replacement sales, country demographics, disease epidemiology and import-export tariffs are some of the major pointers used to forecast the market scenario for individual countries. Also, presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of sales channels are considered while providing forecast analysis of the country data.

Competitive Landscape and Peptide Antibiotics Market Share Analysis

The peptide antibiotics market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to peptide antibiotics market.

Some of the major players operating in the peptide antibiotics market are Merck KGaA, Teva Pharmaceutical Industries Ltd., Pfizer Inc, Mylan N.V., Dr. Reddy’s Laboratories Ltd, Sanofi, GlaxoSmithKline plc., Lilly, Abbott, Novartis AG, Fresenius Kabi AG, Novo Holdings A/S, HENGRUI USA, Allergan Plc, Theravance Biopharma, and Cumberland Pharmaceuticals Inc., among others.

SKU-52384